ROS1 and breast cancer: 18 patients with ROS1+ glioblastoma had PD-L1 testing by SP142 and 33.3% (n = 6/18) were positive while 4 patients with ROS1+ breast cancer had PD-L1 testing by SP142 and 25% (n = 1/4) were positive (data not shown).